No abstract

Summary Squamous cell carcinoma is the cause in most cases of cervical cancer. A very unusual subtype of squamous cell carcinoma is lymphoepithelioma-like carcinoma, found in less than 1% of the neoplasm processes in the uterine cervix. Histologically it looks like a large nest of big-sized tumor cells with large vascular nuclei. Immunohistochemical markers used for LELC are p63, p16, human leukocyte antigen-D related (HLA-DR), and B-cell lymphoma 2. Even though it has aggressive morphological features, it has a better prognosis than most carcinoma cases of the uterine cervix. The condition is treatable, with a hysterectomy and bilateral salpingo-oophorectomy as the most common method. There are rare cases of pelvic lymph node dissection reported in the literature. There is data that lymphoepithelioma-like carcinoma is associated with the Ebstein-Barr virus and human papillomavirus. According to a survey by Tseng et al. and Chao et al., EBV is associated with LELC in Asian women, while HPV is associated with Caucasian women. Due to the small number of studies found in the literature, no conclusion can be drawn concerning the said viruses’ involvement in Asian and Caucasian patients.

Summary Ovarian cancer is not common, but it is still the fifth leading cause of death from malignant diseases among women worldwide. More than 200,000 women are diagnosed with ovarian cancer each year globally. Due to its asymptomatic course, most patients are diagnosed at a late stage. Therefore, ovarian cancer (OC) has the highest mortality among gynecological malignancies. Unfortunately, there is no adequate screening program for the early detection of ovarian cancer, and as a result, this diagnosis escapes clinicians. The protocol for early diagnosis of OC is currently a combination of elevated cancer antigen 125 (CA 125) and transvaginal ultrasonography (TVUS). However, it does not meet the necessary cost-effectiveness criteria and is therefore not recommended by any working group to screen ovarian cancer in the general population. The biomarkers with the highest informative value should be selected individually or combined in multi-biomarker panels from the many biomarkers strongly associated with OC. Numerous such panels of biomarkers and algorithms have been developed for the early diagnosis and differentiation of OC from other benign ovarian diseases. These panels or biomarkers need to be sufficiently reliable and show measurable changes in non-invasive samples obtained from patients with early-stage OC. Their reliability would significantly reduce mortality from this aggressive disease and improve the patient’s prognosis.

Summary Chronic pain syndrome is a severe condition that has been recently recognized, and many methods for treating it have been developed. We present a case of using a pudendal nerve block for treating chronic pain after Bartholin cyst removal. A 46-year-old female presented with chronic pain syndrome, lasting eight months following Bartholin cyst removal. Treatment with non-steroid anti-inflammatory drugs and opioids was unsuccessful, and pudendal nerve block was performed with dexamethasone and ropivacaine. The follow-up continued for a year, and no pain was reported. In cases of pudendal neuralgia, a peripheral pudendal nerve block is effective. Chronic pain syndrome is a complex problem, and a multidisciplinary approach is often required. This case represents the efficacy of pudendal nerve block in chronic pain syndrome after Bartholin cyst removal.

No abstract